Wegovy vs Ozempic UK: Same Drug, Different Licence

You've probably seen the two names used interchangeably. A friend says she's on Ozempic for weight loss, a headline calls Wegovy "the Ozempic jab", and somewhere in the middle you're left wondering whether they're the same thing or two different medicines you're meant to choose between.

The short answer to Wegovy vs Ozempic is that they contain the identical drug. What separates them is the licence, the dose, and what that means for whether you can legally get one of them for weight loss in the UK.

Is Wegovy the same as Ozempic?

Chemically, yes. Both are semaglutide, a GLP-1 receptor agonist made by Novo Nordisk, and both are given as a once-weekly injection under the skin.

Where they part ways is on paper. The Wegovy Summary of Product Characteristics describes it as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with a BMI of 30 or above, or a BMI of 27 to under 30 alongside at least one weight-related health problem. The Ozempic SmPC says something quite different: it's indicated for adults with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise.

Same molecule. Two licences. That distinction drives almost everything else on this page.

If you want the mechanism in more depth, we've written separately about how GLP-1 medications work. The very short version: semaglutide mimics a gut hormone your body already makes after eating, slowing how quickly the stomach empties and dialling down appetite signalling in the brain. At diabetes doses it also improves how your pancreas releases insulin in response to food.

Wegovy vs Ozempic doses

The dosing ladders are the clearest practical difference, and they explain why one is used for weight and the other for blood sugar.

Wegovy climbs over a 16-week period: 0.25mg for weeks one to four, 0.5mg for weeks five to eight, 1mg for weeks nine to twelve, 1.7mg for weeks thirteen to sixteen, then 2.4mg as the maintenance dose.

Ozempic starts in exactly the same place but stops earlier. Its SmPC is blunt about the ceiling: "Weekly doses higher than 2 mg are not recommended." It also notes that 0.25mg is a stepping stone, not a maintenance dose, which surprises people who've been told they're "on the lowest dose long term".

Then there's the newer tier. In January 2026 the MHRA approved a maximum dose of up to 7.2mg per week of semaglutide, given as three 2.4mg injections, and restricted it to adults with obesity at a BMI of 30 or higher. It doesn't apply to people with a BMI under 30, and it doesn't apply to those taking Wegovy purely for cardiovascular risk reduction.

Can you get Ozempic for weight loss in the UK?

Not on licence. The MHRA's own guide to GLP-1 medicines sets it out in a table: Ozempic is licensed to treat diabetes, and it is not licensed for weight loss or weight management. Wegovy is the reverse.

A prescriber can legally prescribe off-label, and some do. But the MHRA adds a line that deserves reading twice: it "has not assessed the safety and effectiveness of these medicines when used outside of their licensed use". You're not just outside the paperwork. You're outside the evidence the regulator reviewed.

There's a practical argument too. If your goal is weight, Wegovy reaches 2.4mg and beyond, where the weight-management trial data sits. Ozempic stops at 2mg. Choosing the diabetes licence for a weight goal means accepting a lower ceiling and a less relevant evidence base, usually for no clinical benefit.

The MHRA is also clear that GLP-1 medicines shouldn't be bought from unregulated sellers, whether that's a beauty salon, a social media seller, or powder in a vial that needs mixing before injection. In December 2025 it urged the public to avoid illegal online weight-loss medicines, warning that products sold this way may be fake, contaminated, incorrectly dosed, or contain ingredients not on the label. If a price looks too good, that's usually why.

How much weight can you expect to lose?

The headline number for Wegovy comes from the STEP 1 trial, published in the New England Journal of Medicine in 2021. Across 1,961 adults over 68 weeks, mean change in body weight was −14.9% with semaglutide 2.4mg compared with −2.4% on placebo, an estimated treatment difference of −12.4 percentage points. In kilograms that was −15.3kg versus −2.6kg.

Averages hide a lot. In the same trial, 86.4% of people on semaglutide lost at least 5% of their body weight and 50.5% lost at least 15%, against 31.5% and 4.9% on placebo. Some people respond far better than the mean suggests. Some respond considerably less.

There is no comparable UK weight-loss figure for Ozempic, because the trials behind its licence were designed to measure blood sugar control rather than weight. Weight reduction appears in its safety data as an observed effect, not as a licensed outcome.

NICE has a useful benchmark here. Its guidance on semaglutide says to consider stopping if less than 5% of initial weight has been lost after six months. That's a sensible checkpoint whoever prescribes for you, and it's worth agreeing one with your clinician before you start rather than three months in.

Side effects: mostly the same, sometimes more

Because it's one molecule, the side-effect profile is broadly shared. Nausea, vomiting, diarrhoea, constipation, indigestion and abdominal pain are the common ones, and they tend to be worst in the fortnight after each dose increase before settling.

The pattern most patients notice is that symptoms track the dose rather than the brand name. Someone stepping up to Wegovy 2.4mg may well have a rougher week than they did at 1mg, and that's true regardless of whether the 1mg came from a Wegovy pen or an Ozempic one.

Rarer but more serious risks include pancreatitis, gallbladder problems and, for people with existing diabetic retinopathy, changes in eye disease. Severe stomach pain that goes through to your back, persistent vomiting, or sudden changes in vision are all reasons to seek medical advice rather than wait for your next review.

We've covered these in more detail in our guides to Ozempic side effects and the downsides of taking Ozempic, and there's a separate piece on facial volume loss, or Ozempic face, which comes up often enough to deserve its own answer.

Cost, the NHS, and getting a prescription

On the NHS, the two medicines sit in completely different places.

Ozempic is prescribed through diabetes care. Wegovy sits under NICE technology appraisal TA875, which recommends semaglutide for weight management only within a specialist weight management service, for a maximum of two years, and only for people with at least one weight-related comorbidity plus either a BMI of 35 or above, or a BMI of 30 to 34.9 who meet the criteria for referral to specialist services. NICE also advises lower BMI thresholds, usually reduced by 2.5, for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.

That specialist-service requirement is why so many people never get Wegovy on the NHS despite technically qualifying. Capacity, not eligibility, is usually the bottleneck. The NHS page on semaglutide puts it plainly: if you need support to lose weight, your doctor will refer you to a specialist weight management service, and you'll only be prescribed semaglutide if your BMI meets the criteria.

For the list prices, NICE published Wegovy at £175.80 per pack for 2.4mg, £124.53 for 1.7mg, and £73.25 for the 0.25mg, 0.5mg and 1mg packs, each pack containing one pen delivering four doses. Those are list prices excluding VAT, not what you'd pay privately, and they predate the 7.2mg dose. Private pricing varies by provider and moves often, so we keep a current breakdown in our Wegovy price guide and our page on NHS eligibility for weight loss injections.

Switching between Wegovy and Ozempic

People move between them for two main reasons: supply, and a change in what they're being treated for.

Someone with type 2 diabetes who also has obesity might be moved from Ozempic to Wegovy so the dose can go higher. Someone taking Wegovy who develops diabetes might have their prescribing reorganised around diabetes care instead. Both are clinical decisions rather than a straight swap you can make yourself, partly because the pens, strengths and dose steps differ.

The practical point is that your current dose usually carries across. If you're stable on Ozempic 1mg, a prescriber is unlikely to send you back to 0.25mg on Wegovy. Where it gets fiddlier is at the top of the Ozempic ladder, since 2mg sits between Wegovy's 1.7mg and 2.4mg steps.

Switching to a different molecule altogether is a separate question. Tirzepatide works on two hormone receptors rather than one, and we compare the two directly in Wegovy vs Mounjaro and in our guide to switching from Mounjaro to Wegovy.

Which one should you be asking about?

If you have type 2 diabetes and blood sugar is the priority, Ozempic is the medicine designed and licensed for that job.

If weight is the reason you're reading this, Wegovy is the licensed answer in the UK. It goes to the doses the weight-management evidence was built on, it's the one regulators have reviewed for this purpose, and it comes with a dosing route that continues past the point where Ozempic stops.

And if you have both, that's a conversation worth having properly with a clinician rather than settling from a website. The right answer depends on your HbA1c, your BMI, what else you're taking, and how your NHS diabetes care is organised.

One more option you may come across: semaglutide is now also available as a tablet. We've looked at what that means for people who'd rather not inject in our guide to GLP-1 tablets in the UK. And if you're starting injections for the first time, our piece on where to inject Wegovy covers technique and site rotation.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.